Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7625A in Japanese patients with cUTI/pyelonephritis
NCT02728089Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of ceftolozane + tazobactam in complicated urinary tract infection (cUTI) and pyelonephritis, sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC) at Day 14, Percentage of Participants Who Report 1 or More Adverse Event (AE) up to 42 days and 1 more. Started Apr 2016; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
complicated urinary tract infection (cUTI)pyelonephritis
Beyond the preview
Go deeper on NCT02728089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728089.